Method for detecting cytosine methylation in DNA samples

• US 7,524,629 B2
• Filed: 02/23/2001
• Issued: 04/28/2009
• Est. Priority Date: 02/25/2000
• Status: Expired due to Fees

• Current Assignee: Epigenomics AG
• Original Assignee: Epigenomics AG
• Inventors: Olek, Alexander, Berlin, Kurt
• Primary Examiner(s): GOLDBERG, JEANINE ANNE
• Application Number:
  US10/220,090
• Publication Number:
  US 20030129620A1
• Time in Patent Office: 2,986 Days
• Field of Search: 435/6, 435/91.1, 435/91.2, 536/23.1, 536/24.3
• US Class Current: 435/6.1
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6858 Allele-specific amplification
• CPC Class Codes: C12Q 2523/125 Bisulfite(s)
• CPC Class Codes: C12Q 2535/125 Allele specific primer extension
• CPC Class Codes: C12Q 2565/537 characterised by the capture oligonucleotide acting as a primer

Abstract

Described is a method for detecting 5-methylcytosine in genomic DNA samples. First, a genomic DNA from a DNA sample is chemically converted with a reagent, 5-methylcytosine and cytosine reacting differently, and the pretreated DNA is subsequently amplified using a polymerase and at least one primer. In the next step, the amplified genomic DNA is hybridized to at least one oligonucleotide, forming a duplex, and said oligonucleotide is elongated by at least one nucleotide, the nucleotide carrying a detectable label, and the elongation depending on the methylation status of the specific cytosine in the genomic DNA sample. In the next step, the elongated oligonucleotides are analyzed for the presence of the label.

Claims

1. A method for concurrently detecting 5-methylcytosine and SNP in genomic DNA samples, characterized in that the following steps are carried out:

(a) chemically converting a genomic DNA from a DNA sample with a reagent, 5-methylcytosine and cytosine reacting differently, thus exhibiting different base pairing behaviors in the DNA duplex subsequent to the reaction;

(b) amplifying the pretreated DNA using a polymerase and at least one oligonucleotide (type A) as a primer;

(c) hybridizing the amplified genomic DNA to at least one oligonucleotide (type B), forming a duplex, said hybridized oligonucleotides of type B, with their 3′

-ends, immediately or at a distance of up to 10 bases, adjoining the positions to be analyzed with regard to their methylation in the genomic DNA sample;

(d) elongating the oligonucleotide (type B) having a known sequence of n nucleotides by means of a polymerase by a plurality of nucleotides, at least one nucleotide carrying a detectable label, and the elongation depending on the methylation status of the specific cytosine in the genomic DNA sample and on a single nucleotide polymorphism;

(e) analyzing the elongated oligonucleotides for the presence of the label; and

(f) deducing the presence of said 5-methylcytosine and SNP in the genomic DNA samples from the incorporated label.

2. The method as recited in claim 1, characterized in that the oligonucleotides (type B) are bonded to a solid phase at defined locations.

3. The method as recited in claim 1, characterized in that the amplificates are bonded to a solid phase at defined locations.

4. The method as recited in claim 2, characterized in that different oligonucleotide sequences are arranged on a plane solid phase in the form of a rectangular or hexagonal lattice.

5. The method as recited in claim 4, characterized in that the labels attached to the elongated oligonucleotides are identifiable at each position of the solid phase at which an oligonucleotide sequence is located.

6. The method as recited in claim 1, characterized in that at least one primer (type A) is bonded to a solid phase during amplification.

7. The method as recited in claim 1, characterized in that different amplificates are arranged on the solid phase in the form of a rectangular or hexagonal lattice.

8. The method as recited in claim 1, characterized in that, prior to the amplification, the DNA is treated with a bisulfite solution (=disulfite, hydrogen sulfite).

9. The method as recited in claim 1, characterized in that the amplification is carried out by means of the polymerase chain reaction (PCR).

10. The method as recited in claim 1, characterized in that the oligonucleotides of type A used either contain only the bases T, A and C or else the bases T, A and G.

11. The method as recited in claim 1, characterized in that the oligonucleotides of type B used either contain only the bases T, A and C or else the bases T, A and G.

12. The method as recited in claim 1, characterized in that the labels of the nucleotides are fluorescence labels.

13. The method as recited in claim 1, characterized in that the labels of the nucleotides are radionuclides.

14. The method as recited in claim 1, characterized in that the labels of the nucleotides are detachable mass labels which are detected in a mass spectrometer.

15. The method as recited in claim 1, characterized in that the elongated oligonucleotides altogether are detected in the mass spectrometer, thus being uniquely labeled by their masses.

16. The method as recited in claim 1, characterized in that in each case one fragment of the elongated oligonucleotides is detected in the mass spectrometer.

17. The method as recited in claim 15, characterized in that the fragment of the elongated oligonucleotide is produced by digestion with one or several exo- or endonucleases.

18. The method as recited in claim 16, characterized in that the produced fragments have a single positive or negative net charge for better detectability in the mass spectrometer.

19. The method as recited in claim 1, characterized in that the detection of the elongated oligonucleotides is carried out and visualized by means of matrix assisted laser desorption/ionization mass spectrometry (MALDI) or using electron spray mass spectrometry (ESI).

20. The method as recited in claim 1, wherein the polymerases are heat-resistant DNA-polymerases.

21. The method as recited in claim 1, wherein the used nucleotides are terminating (type C 2) and/or chain-elongating nucleotides (type C 1).

22. The method as recited in claim 21, wherein the chain-terminating nucleotide (type C 2) is selected from a group comprising either the bases T and C or else the bases G and A.

23. The method as recited in claim 21, wherein the chain-elongating nucleotides (type C 1) are selected from a group comprising either the nucleobases A, T and C or else the bases G and A and T.

24. The method as recited in claim 1, characterized in that the amplification of several DNA segments is carried out in one reaction vessel.

25. The method as recited in claim 23, characterized in that the fluorescently labeled dCTP-derivate is Cy3-dCTP or Cy5-dCTP.

26. The method as recited in claim 2, characterized in that solid phase surface is composed of silicon, glass, polystyrene, aluminum, steel, iron, copper, nickel, silver, or gold.

27. The method as recited in claim 1, wherein the genomic DNA is obtained from a DNA sample, sources of DNA comprising, e.g., cell lines, blood, sputum, stool, urine, cerebral-spinal fluid, tissue embedded in paraffin, histologic object slides, and all possible combinations thereof.

28. The method as recited in claim 1, characterized in that methylation analyses of the upper and lower DNA strands are carried out.

29. The method as recited in claim 1, wherein the oligonucleotide (type B) having a known sequence of n nucleotides is elongated by up to ten nucleotides.